An observational study in Major Depressive Episode, Major Depressive Disorder and Borderline Personality Disorder, sponsored by University of Oldenburg. Completed at 1 site in Germany. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-12-11.
Sponsored by University of Oldenburg · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 164 studies in Depressive Disorder, Major with a site in Germany — 26 open to participants now, 27 under way, 5 of them phase 3. Depressive Disorder, Major · Germany.
Among the 164 studies in Depressive Disorder, Major with a site in Germany, this one is the 8th largest by enrollment of the 13 observational ones that give a count, is one of 11 that started in 2021, is one of 13 observational ones, and was the 117th registered.
3,051 studies on the registry are indexed under Depressive Disorder, Major; 596 are open to participants now.
Browse Depressive Disorder, Major studies →26 of the 164 studies in Depressive Disorder, Major with a site in Germany are open now. Recruiting first, the newest first:
Eli Lilly and Company · Sites in Germany, United States, Australia and 12 more countries
Ages 18–75
Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico · Sites in Germany, Italy, Spain
Ages up to 45 · Healthy volunteers
University of Regensburg · Sites in Germany
Ages 18–70
Eli Lilly and Company · Sites in Germany, United States, Australia and 12 more countries
Ages 18–75
Cybin IRL Limited · Sites in Germany, United States, Australia and 5 more countries
Ages 18–85
A study can be open while its sites in Germany have not opened yet or have stopped. Only those recruiting at a site in Germany →
Of the 419 Depressive Disorder, Major studies recruiting now, 93 (22%) set no upper age limit and 299 (71%) stop at 75 or younger; 55 take children under 18; 100 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
164 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 11 · Phase 2 29 · Phase 3 51 · Phase 4 10
First in 1998; this study’s year is marked. 11 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 102 is below the median of 132 across 403 observational studies indexed under Depressive Disorder, Major.
Median enrollment 176 across the 150 interventional studies, 104 across the 13 observational. Of the 124 that completed or were terminated, 43 (35%) have results posted.
This tab as a report to print or save as PDF → With an account.
80 of 164 have an industry lead sponsor. The 10 most frequent:
University of Oldenburg is the lead sponsor of 6 studies on the registry; 1 is open to participants now.
University of Oldenburg has 1 study filed under Depressive Disorder, Major — fewer than ten, so there is no comparison to draw.
10 of the studies in Depressive Disorder, Major with a site in Germany that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07076407Phase 3Xenon Pharmaceuticals Inc.A Randomized Study of Azetukalner Versus Placebo in Major Depressive Disorder (X-NOVA3) | 2027-05 |
| NCT06793397Phase 3Cybin IRL LimitedA Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressive Disorder | 2027-06-07 |
| NCT06389175University of BonnNon-invasive Vagus Nerve Stimulation as a Tool to Modulate Stomach-Brain Coupling in Depression | 2026-12 |
| NCT07197138Max-Planck-Institute of PsychiatryIMPACT-D+: Immune-Modulating and Psychometric Effects of Accelerated TMS in Depression Plus Comorbid Post-COVID-19 Condition | 2027-01 |
| NCT07065240Seaport TherapeuticsA Study to Evaluate the Efficacy and Safety of SPT-300 (GlyphAllo) in Participants With Major Depressive Disorder, With or Without Anxious Distress (BUOY-1 Study) | 2027-03 |
Add all 10 to your calendar (.ics) → With an account.
Among the 164 studies in Depressive Disorder, Major with a site in Germany, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Advances in repetitive transcranial magnetic stimulation (rTMS) protocols with intermittent theta-burst stimulation (iTBS) have significantly decreased the duration for one single session and thereby enabled accelerated treatment plans with multiple sessions per day, potentially reducing the total treatment duration. This randomized, placebo-controlled study investigates the effects of accelerated iTBS treatment with connectivity-informed neuronavigation on symptom severity, sleep, interoception, and cognitive control in patients with major depressive disorder and with or without comorbid borderline personality disorder using magnetic resonance imaging (MRI).
Repetitive transcranial magnetic stimulation (rTMS) is a safe and efficacious treatment option for treatment-resistant depression. Advances in rTMS protocols with intermittent theta-burst stimulation (iTBS) have significantly decreased the duration for one single session and thereby enabled accelerated treatment plans with multiple sessions per day, potentially reducing the total treatment duration. Major depressive disorder (MDD) is characterized by impairments in various domains including sleep, impulse control, and interoception. Borderline personality disorder (BPD) is characterized by fear of abandonment, mood swings, and an unstable perception of self and often occurs with comorbid MDD. This comorbidity frequently impedes treatment of the BPD.
In this randomized, placebo-controlled study, 60 patients with treatment-resistant MDD (30 verum group, 30 sham group) and 60 patients with treatment-resistant MDD and comorbid BPD (30 verum group, 30 sham group) will receive two weeks of connectivity-informed iTBS of the left dorsolateral prefrontal cortex (DLPFC; 3 sessions per day, 5 days per week). Before and after the treatment phase, (functional) magnetic resonance imaging (fMRI) will be performed. The effects of iTBS will be tested in four domains: (1) symptom severity (MDD and BPD symptoms), (2) sleep quality (sleep questionnaires and various sleep parameters monitored via an electroencephalography (EEG) headband), (3) neurocognitive effects (vigilance and response inhibition measured with behavioral and fMRI tasks), and (4) interoception (interoceptive attention measured with behavioral and fMRI tasks). Furthermore, before the start of the two-weeks treatment, a single iTBS session ("forecaster session") will be conducted to explore the validity of early symptom/mood responses and hormonal changes for the prediction of the the treatment outcome. Treatment effects will be analyzed within and across patient groups (MDD and MDD + BPD). In addition, domain-specific treatment effects will be analyzed as a function of distinct iTBS targets within the DLPFC.To evaluate pathological biases, the investigators will compare the patients' data with a control group of 30 healthy participants who will also be tested twice (without iTBS).
Patients at the Department of Psychiatry, University of Oldenburg. The patients' diagnosis of MDD and BPD will be verified via the structured clinical interview for DSM-V. Healthy controls will be matched to the patient sample.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
DSM diagnostic criteria
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
At least one failed pharmaco trial in current episode
Device: intermittent theta burst stimulation (iTBS) or sham stimulation
At least one failed pharmaco trial in current episode
Device: intermittent theta burst stimulation (iTBS) or sham stimulation
No psychiatric disorders
30 sessions of iTBS over 2 weeks (3 sessions per day, 5 days per week)
Change in depression severity after the treatment phase
Measured with the Montgomery Asberg Rating Scale (MARDS). Remission defined as MADRS score (range: 0 to 60) of less than or equal to 10. Response defined as a reduction of at least 50 percent from baseline in MADRS score.
Time frame: Up to 5 weekdays after the last iTBS treatment session
Change in BPD severity after the treatment phase
Measured by the Zanarini rating scale for BPD (Zan-BPD, range 0-36). Remission is defined as score of 9 or less. Response defined as a decrease from baseline in Zan-BPD score of at least 20 percent of the scoring range, i.e. a reduction of 8 points or more.
Time frame: Up to 5 weekdays after the last iTBS treatment session
Changes in neural responses in an interoception task before the first and after the last treatment session
Measured with functional magnetic resonance imaging (fMRI) while performing an interoception task
Time frame: Up to 5 weekdays before the first and after the last treatment session
Changes in neural responses in a cognitive control task before the first and after the last treatment session
Measured with functional magnetic resonance imaging (fMRI) while performing a cognitive control task
Time frame: Up to 5 weekdays before the first and after the last treatment session
Changes in behavioral responses in an interoception task before the first and after the last treatment session
Measured as performance in an interoception task during fMRI
Time frame: Up to 5 weekdays before the first and after the last treatment session
Changes in behavioral responses in a cognitive control task before the first and after the last treatment session
Measured as performance in a cognitive control task during fMRI
Time frame: Up to 5 weekdays before the first and after the last treatment session
Changes in sleep staging over the treatment course
electroencephalography (EEG)-based sleep staging measured with a headband device with accelerometer and pulseoximeter
Time frame: 2 days of baseline measurement before the first iTBS session, daily over the treatment course for 10 days
Changes in brain connectivity measures
Structural and functional connectivity measured with MRI including graph measures
Time frame: Up to 5 weekdays before the first and after the last treatment session
Changes in vigilance over the treatment course
Vigilance measured by Psychomotor Vigilance Task (PVT)
Time frame: Baseline immediately before the first iTBS session, daily over the treatment course for 10 days
Changes in symptom severity over treatment course
Measured by the MADRS
Time frame: Baseline immediately before the first iTBS session, after 1 week of treatment, after 2 weeks of treatment, and at the follow-up 6 weeks after treatment
Changes in self-reported symptom severity over treatment course and at follow-up
measured by the Beck Depression Inventory (BDI-II)
Time frame: Baseline immediately before the first iTBS session, daily over the treatment course for 10 days, 6 weeks after last iTBS session at the follow-up
Changes in Cortisol Awakening Response (CAR) from saliva concentrations
3 measurements after awakening (0,20, and 40 minutes)
Time frame: Up to 5 weekdays before the first and after the last treatment session
Changes in blood parameters
Pro- and anti-inflammatory cytokines, and growth factors
Time frame: Before the first and after the last treatment session
Association between changes induced by the Forecaster session and treatment outcome
Changes in biomarkers before and after the forecaster iTBS session
Time frame: Immediately before and after the forecaster iTBS session
Changes in self-reported BPD symptom severity over treatment course and at follow-up
Measured by the Borderline Symptom List (BSL-23) (range 0-4)
Time frame: Baseline immediately before the first iTBS session, daily over the treatment course for 10 days, 6 weeks after last iTBS session at follow-up
Changes in BPD symptom severity over treatment course and at follow-up
Measured by Zan-BPD
Time frame: Baseline immediately before the first iTBS session, after 1 week of treatment, and after 2 weeks of treatment
Changes in food craving
Measured by a behavioral food craving task
Time frame: Up to 5 weekdays before the first and after the last treatment session
Plan to share: Undecided
Ran from May 2021 to primary completion in Jun 2024, 37 months.
Of 121 non-industry observational studies under Depressive Disorder, Major, half reached primary completion within 46 months of starting (the median), counting those still running; a quarter within 29 and three quarters within 73. This study's 37 months is below that.
Counting every sponsor, half of 150 studies reached it within 38 months; a quarter within 21 and three quarters within 67.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Dec 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University of Oldenburg